Management of asymptomatic hyperuricemia.
Although the incidence of gout, renal stones, or both is increased in patients with hyperuricemia, there is no evidence that long-term therapy offers any substantial long-term benefits. Recent data also suggest that no clear relationship exists between hyperuricemia and the development of interstitial nephritis (so-called urate nephropathy). Finally, the relationship between elevations in the serum concentration of uric acid and the risk of developing cardiovascular disease remains undefined. It is recommended that, in a patient with asymptomatic hyperuricemia, a conservative approach be taken and hypouricemic therapy not be instituted as a matter of routine.
D000208:Acute Disease; D002318:Cardiovascular Diseases / Q000209:etiology; D003657:Decision Making; D006073:Gout / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy / Q000209:etiology; D012306:Risk; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents / Q000627:therapeutic use*
D014528:Uricosuric Agents; D014527:Uric Acid